RheumNow Podcast – Mistakes with Steroids
Dr Jack Cush gives his spin on this week's RheumNews and Rheum Research from RheumNow.com.
Read ArticleDr Jack Cush gives his spin on this week's RheumNews and Rheum Research from RheumNow.com.
Read ArticleA survey study from the ArthritisPower PPRN or CreakyJoints database shows that during the COVID-19 pandemic patient care was substantially affected in unforeseen ways.
Data from the ArthritisPower Patient-Powered Research Network and CreakyJoints patient community were gathered by
Read ArticleDr Jack Cush reviews the news and Journal reports and takes "Back Talk" questions from viewers.
Read ArticleMcInnes and colleagues have published the results of the SELECT - PsA trial in NEJM showing updacitinib (UPA) to be superior to placebo in active psoriatic arthritis (PsA) patients, with 15 mg UPA equal to adalimumab (ADA) and 30 mg UPA qd being superior to ADA.
Janus kinase
Read ArticleThe European Journal of Preventive Cardiology reports that younger patients with their first myocardial infarction before age 50 yrs have a higher risk of having a systemic inflammatory disease (SIDs) and higher rates all-cause mortality.
Data derived from the retrospective
Read ArticleLinks:
Dr. John Cush @RheumNow( View Tweet )
This year’s coverage of psoriatic arthritis was once again, both exciting and informative. Topics included an overview of the latest therapeutic options, an excellent discussion on psoriasis specifically, and the epidemiology of psoriatic arthritis.
Read ArticleDr. John Cush @RheumNow( View Tweet )
Links:
Dr. John Cush @RheumNow( View Tweet )
Links:
Dr. John Cush @RheumNow( View Tweet )
Dr. Jack Cush rants on the journal reports, news and FDA actions featured this past week on RheumNow.com.
Read ArticleSeveral weeks ago, at the Rheumatology Winter Clinical Symposia, an interesting debate between Drs. Orrin Troum and Marty Bergman hashed over the concept of whether rheumatologists should sub-specialize with a practice, research or career devoted to one disease ("Super Rheum"), or be "selective
Read ArticlePalmoplantar psoriasis (PPP) is a therapeutically challenging variant of psoriasis; nonetheless, a prospective, randomized, active-controlled trial from India suggests that apremilast is effective and safe in patients with PPP.
Read ArticleLinks:
Dr. John Cush @RheumNow( View Tweet )
Schett and colleagues studies the secukinumab (an IL-17 inhibitor) response in patients from 3 clinical trials with enthesitis and ankylosing spondylitis (AS) and demonstrated consistent efficacy with improved enthesitis scores at both peripheral and axial sites.
Pooled data from the
Read ArticlePatients with rheumatic diseases who developed COVID-19 were at increased likelihood of death, with risk factors similar to those seen in the general population but also because of factors specific to their underlying disease and its treatment, analysis of data from an international registry
Read ArticleLinks:
Incident or worsening colitis is a rare complication of IL-17 inhibitor therapy; a real world study confirms very low rates of new IBD in patients starting secukinumab.
A real-world study of the secukinumab (SEC; an IL-17 inhibitor) and gastrointestinal related adverse events (GIRAE)
Read ArticleDr. Jack Cush reviews and discusses nearly a dozen news reports and journal articles from the past week on RheumNow.com.
Read ArticleLinks:
Dr. John Cush @RheumNow( View Tweet )
Links:
Dr. John Cush @RheumNow( View Tweet )
The results of the novel MAXIMISE trial have been published, demonstrating that secukinumab significantly improved axial signs and symptoms in psoriatic arthritis patients with axial manifestations with inadequate NSAID response.
Read ArticleLinks:
Dr. John Cush @RheumNow( View Tweet )
Dr. Jack Cush reviews and discusses the news and Journal reports from the past week on RheumNow.com.
Read Article